Xenetic Biosciences, Inc.

Home
United States
Framingham, MA
Xenetic Biosciences, Inc.

XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Ltd.

Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

09/10/2025

Our lead program is advancing toward new treatments for — the third deadliest cancer in the U.S., with 62,000 diagnoses and 50,000 deaths each year.

08/27/2025

Our data suggests NETs degradation by DNase I plays a crucial role in maintaining CAR T-cell function and preventing premature CAR T-cell exhaustion.

Learn more: https://bit.ly/4mJ0Qzy

08/22/2025

At Xenetic, we remain committed to advancing our systemic recombinant human DNase I technology into the clinical stage.

08/18/2025

Our DNase I Platform employs an enzyme designed to eliminate NETs. Discover more here: https://bit.ly/47DW931

08/13/2025

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

https://bit.ly/3JcVzkQ

08/12/2025

Explore everything you need to know about in our latest investor deck.

Take a look: https://bit.ly/3LgHpg2

08/06/2025

:Our collaboration partner PeriNess announced that Bnei Zion Medical Center started patient dosing in a study testing systemic I with FOLFIRINOX for first-line treatment of unresectable, locally advanced, or metastatic .

https://bit.ly/40Hrdwq

07/31/2025

Our oncology platform is designed to improve cancer therapies, with the potential to address multiple oncology indications — including and other .

Find out more: https://bit.ly/3PkEMfi

07/30/2025

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

https://bit.ly/4oePaWi

07/23/2025

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

https://bit.ly/3GSLdpu

Xenetic Biosciences, Inc. does not review or control the content of any non-Xenetic Biosciences, Inc. site. Xenetic Biosciences, Inc. does not endorse and is not responsible for the accuracy, content, practices, or standards of any non-Xenetic Biosciences, Inc. sites.

07/14/2025

: James F. Parslow, Interim CEO & CFO, brings 35+ years of leadership across biotech, clean tech, e-commerce and high-tech manufacturing.

He’s led strategy, capital markets, M&A, and investor relations with a strong track record of driving growth and performance.

🔗 Read more: https://bit.ly/4dd8mx0

07/11/2025

Stay in the know with XBIO! 🚀
Get email alerts and be the first to hear about our latest news, updates and breakthroughs.

Sign up today and never miss an update!
https://bit.ly/3MTgAiR

Address

40 Speen Street
Framingham, MA
01701

Telephone

+17817787720

Website

http://www.xeneticbio.com/

Alerts

Be the first to know and let us send you an email when Xenetic Biosciences, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Xenetic Biosciences, Inc.:

Featured

Cannamed Boston
475 Franklin Street , Suite 205

Want your practice to be the top-listed Clinic in Framingham?

Our Story

Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.